| Literature DB >> 28660052 |
Chanwoo Kim1, Jinjoo Jung2, Truong T Tung1, Seung Bum Park1,2.
Abstract
For the systematic perturbation of protein-protein interactions, we designed and synthesized tetra-substituted hexahydro-4H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H)-diones as β-turn mimetics. We then devised a new synthetic route to obtain β-turn mimetic scaffolds via tandem N-acyliminium cyclization and constructed a 162-member library of tetra-substituted pyrazinotriazinediones with an average purity of 90% using a solid-phase parallel synthesis platform. Each library member was subjected to ELISA-based modulator screening for the LRS-RagD interaction, which plays a pivotal role in the nutrient-dependent mTORC1 signalling pathway. Western blot analysis of phosphorylated S6K1 as well as FRET-based imaging confirmed that 5c{3,9} stabilizes the direct interaction between LRS and RagD and activates mTORC1 in live cells under leucine-deprived conditions. Thus, 5c{3,9} can be used as a new research tool for studying the non-canonical role of LRS.Entities:
Year: 2015 PMID: 28660052 PMCID: PMC5477029 DOI: 10.1039/c5sc03493k
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1Roles of leucyl-tRNA synthetase. (i) Canonical role (left circle) of leucyl-tRNA synthetase; LRS conjugates leucine and cognate tRNA. (ii) Non-canonical role (right circle) of LRS–leucine-dependent mTORC1 activation; LRS binds to RagD and activates mTORC1 in a leucine-dependent manner.
Fig. 2(A) Schematic diagram of a β-turn structure. (B) Overlay of a potential mode of β-turn mimicry with a tetra-substituted hexahydro-4H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H)-dione. (C) Distance between substituents in the energy-minimized conformer of its tetra-substituted representative analog 7 containing 4-methylphenyl, benzyl, butyl, and 4-chlorophenyl at the R1–R4 positions, respectively. (D) Alignment of an energy-minimized structure of representative compound 7 with the peptide backbone structure of phospholipase A2 β-turn motif (PDB: ; 4BP2).
Fig. 3Retrosynthetic analysis of tetra-substituted hexahydro-4H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H)-dione (1).
Scheme 1General synthesis scheme for acid partners (A) and tetra-substituted hexahydro-4H-pyrazino[2,1-c][1,2,4]triazine-4,7(6H)-dione (B). Reagents and conditions: (i) R2-isocyanate, TEA, THF, 0 °C to r.t., 5 h, then t-butyl bromoacetate, KHCO3, DMF, 80 °C, 12 h; (ii) 4 N HCl, 1,4-dioxane, r.t., overnight; (iii) Boc2O, NaHCO3, THF/H2O (1 : 1 v/v), r.t., overnight, then R2-isocyanate, TEA, THF, 0 °C to r.t., 5 h; (iv) 4 N HCl, 1,4-dioxane, r.t., then t-butyl bromoacetate, K2CO3, toluene/DMF (8 : 1 v/v), reflux, 12 h; (v) R3-NH2, DMSO, 60 °C, 12 h; (vi) Fmoc-amino acid, HCTU [O-(6-chlorobenzotriazol-1-yl)-N,N,N′,N′-tetra-methyluronium hexafluorophosphate], DIPEA, DMF, r.t., 4 h; (vii) 20% piperidine, DMF, r.t., 10 min; (viii) acid coupling partner (A-1), HOBt [hydroxybenzotriazole], DIC [N,N′-diisopropylcarbodiimide], DMF, r.t., 3 h; (ix) acid coupling partner (A-2), HOBt, DIC, DMF, r.t., 3 h; (x) formic acid, r.t., 18 h.
Purity and mass conformation of representative compounds
| R1 | R2 | R3 | R4 | Purity | MS[M + H]+ | ||
| Calcd | Found | ||||||
|
|
|
|
|
| 91 | 574.25 | 574.22 |
|
|
|
|
|
| 96 | 492.29 | 492.04 |
|
|
|
|
|
| 99 | 530.27 | 530.03 |
|
|
|
|
|
| 93 | 524.26 | 524.15 |
|
|
|
|
|
| 98 | 558.22 | 558.20 |
|
|
|
|
|
| 90 | 753.31 | 753.67 |
|
|
|
|
|
| 90 | 512.26 | 512.32 |
|
|
|
|
|
| 95 | 514.24 | 514.06 |
Purities in percentage were obtained using PDA (photodiode array)-based LC/MS analysis of crude final compounds after a short filter column. Pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran.
Fig. 4(A) Two possible trajectories of the nitrogen nucleophile (pathways a & b) via tandem N-acyliminium cyclization. (B) Representative compound 9 and its 2D-NMR NOE data.
Purity table of all final compounds
|
|
|
|
Purities (%) were obtained using PDA-based LC-MS analysis of crude final compounds after a short filter column (average purities: 90%).
Fig. 5(A) Structure–activity relationship study of PPI stabilizers between LRS–RagD among our β-turn mimetic compounds. Compounds with hydrophobic and aromatic substituents (black) showed better stabilizing activity than others (grey). (B) HEK293T cells were starved of leucine for 1 h and treated with 20 μM compounds for 3 h under leucine-deprived conditions. Phospho-S6K1 (T389), S6K1, and GAPDH were determined using western blot. HEK293T cells treated with 0.6 mM leucine were used as a control. (C) Quantification of western blotting against a DMSO control.
Fig. 6(A) Structure of the hit compound, 5c{3,9}. (B) ELISA-based evaluation of LRS and RagD stabilization by 5c{3,9} in a dose-dependent manner. (C) Schematic representation of FRET between LRS-CFP and RagD-YFP. When LRS directly interacts with RagD, LRS-fused CFP is physically close to RagD-fused YFP, generating a FRET signal. Fluorescence of 475 nm from CFP with excitation at 433 nm transfers to YFP and emits fluorescence at 527 nm. (D) Relative FRET efficiency ratio between LRS-CFP and RagD-YFP in HEK293T cells co-transfected with LRS-CFP and RagD-YFP. Images were taken at 10 min intervals over 3.5 h in a single cell. Cells were randomly selected from 3 independent experiments (P = 0.002; Mann–Whitney Test). 5c{3,9} (clear square) or 5a{2,9} (reverse black triangle) was treated at a 40 μM concentration after an initial 30 min of live cell imaging. Images were captured with CFP/CFP, CFP/YFP, and YFP/YFP filters (excitation/emission). Captured FRET images were analyzed using Softworks (imaging software) to exclude false-positive signal such as CFP crosstalk and YFP crosstalk. (E) Representative calculated FRET within cells. The color scale indicates the range of FRET intensity, from low (blue) to high (red). Scale bar, 20 μm.